148 related articles for article (PubMed ID: 24114765)
1. Sequence-dependent combination therapy with doxorubicin and a survivin-specific small interfering RNA nanodrug demonstrates efficacy in models of adenocarcinoma.
Ghosh SK; Yigit MV; Uchida M; Ross AW; Barteneva N; Moore A; Medarova Z
Int J Cancer; 2014 Apr; 134(7):1758-66. PubMed ID: 24114765
[TBL] [Abstract][Full Text] [Related]
2. Image-guided breast tumor therapy using a small interfering RNA nanodrug.
Kumar M; Yigit M; Dai G; Moore A; Medarova Z
Cancer Res; 2010 Oct; 70(19):7553-61. PubMed ID: 20702603
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin induces cell death in breast cancer cells regardless of Survivin and XIAP expression levels.
Nestal de Moraes G; Vasconcelos FC; Delbue D; Mognol GP; Sternberg C; Viola JP; Maia RC
Eur J Cell Biol; 2013; 92(8-9):247-56. PubMed ID: 24064045
[TBL] [Abstract][Full Text] [Related]
4. Cascade therapy with doxorubicin and survivin-targeted tailored nanoparticles: An effective alternative for sensitization of cancer cells to chemotherapy.
Daglioglu C; Kaci FN
Int J Pharm; 2019 Apr; 561():74-81. PubMed ID: 30825555
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Effects of AICAR and DOX Conjugated Multifunctional Nanoparticles in Sensitization and Elimination of Cancer Cells via Survivin Targeting.
Daglioglu C; Okutucu B
Pharm Res; 2017 Jan; 34(1):175-184. PubMed ID: 27783307
[TBL] [Abstract][Full Text] [Related]
6. Enhanced Lysosomal Escape of pH-Responsive Polyethylenimine-Betaine Functionalized Carbon Nanotube for the Codelivery of Survivin Small Interfering RNA and Doxorubicin.
Cao Y; Huang HY; Chen LQ; Du HH; Cui JH; Zhang LW; Lee BJ; Cao QR
ACS Appl Mater Interfaces; 2019 Mar; 11(10):9763-9776. PubMed ID: 30776886
[TBL] [Abstract][Full Text] [Related]
7. Combination Therapy of Breast Cancer by Codelivery of Doxorubicin and Survivin siRNA Using Polyethylenimine Modified Silk Fibroin Nanoparticles.
Norouzi P; Motasadizadeh H; Atyabi F; Dinarvand R; Gholami M; Farokhi M; Shokrgozar MA; Mottaghitalab F
ACS Biomater Sci Eng; 2021 Mar; 7(3):1074-1087. PubMed ID: 33539074
[TBL] [Abstract][Full Text] [Related]
8. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
[TBL] [Abstract][Full Text] [Related]
9. Combination of survivin siRNA with neoadjuvant chemotherapy enhances apoptosis and reverses drug resistance in breast cancer MCF-7 cells.
Dong H; Yao L; Bi W; Wang F; Song W; Lv Y
J Cancer Res Ther; 2015; 11(4):717-22. PubMed ID: 26881507
[TBL] [Abstract][Full Text] [Related]
10. The suppression of metastatic lung cancer by pulmonary administration of polymer nanoparticles for co-delivery of doxorubicin and Survivin siRNA.
Xu C; Tian H; Wang P; Wang Y; Chen X
Biomater Sci; 2016 Oct; 4(11):1646-1654. PubMed ID: 27709139
[TBL] [Abstract][Full Text] [Related]
11. Co-delivery of cisplatin and doxorubicin by covalently conjugating with polyamidoamine dendrimer for enhanced synergistic cancer therapy.
Guo XL; Kang XX; Wang YQ; Zhang XJ; Li CJ; Liu Y; Du LB
Acta Biomater; 2019 Jan; 84():367-377. PubMed ID: 30528609
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of survivin expression and enhanced chemosensitivity of MCF-7 cells to adriamycin by PDMAE/survivin shRNA complex nanoparticles.
Yang Y; Gao Y; Chen L; Huang Y; Li Y
Int J Pharm; 2011 Feb; 405(1-2):188-95. PubMed ID: 21130850
[TBL] [Abstract][Full Text] [Related]
13. Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo.
Meng H; Mai WX; Zhang H; Xue M; Xia T; Lin S; Wang X; Zhao Y; Ji Z; Zink JI; Nel AE
ACS Nano; 2013 Feb; 7(2):994-1005. PubMed ID: 23289892
[TBL] [Abstract][Full Text] [Related]
14. Ultrasound-Guided Delivery of siRNA and a Chemotherapeutic Drug by Using Microbubble Complexes: In Vitro and In Vivo Evaluations in a Prostate Cancer Model.
Bae YJ; Yoon YI; Yoon TJ; Lee HJ
Korean J Radiol; 2016; 17(4):497-508. PubMed ID: 27390541
[TBL] [Abstract][Full Text] [Related]
15. miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.
Hu Y; Xu K; Yagüe E
Breast Cancer Res Treat; 2015 Jun; 151(2):269-80. PubMed ID: 25900794
[TBL] [Abstract][Full Text] [Related]
16. HIF-2α dictates the susceptibility of pancreatic cancer cells to TRAIL by regulating survivin expression.
Harashima N; Takenaga K; Akimoto M; Harada M
Oncotarget; 2017 Jun; 8(26):42887-42900. PubMed ID: 28476028
[TBL] [Abstract][Full Text] [Related]
17. Combination of Nanovectorized siRNA Directed against Survivin with Doxorubicin for Efficient Anti-Cancer Activity in HER2+ Breast Cancer Cells.
Eljack S; Allard-Vannier E; Misericordia Y; Hervé-Aubert K; Aubrey N; Chourpa I; Faggad A; David S
Pharmaceutics; 2022 Nov; 14(11):. PubMed ID: 36432729
[TBL] [Abstract][Full Text] [Related]
18. siRNAs targeting multidrug transporter genes sensitise breast tumour to doxorubicin in a syngeneic mouse model.
Tiash S; Chowdhury EH
J Drug Target; 2019 Mar; 27(3):325-337. PubMed ID: 30221549
[TBL] [Abstract][Full Text] [Related]
19. siRNA inhibition of telomerase enhances the anti-cancer effect of doxorubicin in breast cancer cells.
Dong X; Liu A; Zer C; Feng J; Zhen Z; Yang M; Zhong L
BMC Cancer; 2009 May; 9():133. PubMed ID: 19416503
[TBL] [Abstract][Full Text] [Related]
20. EpCAM Aptamer-mediated Survivin Silencing Sensitized Cancer Stem Cells to Doxorubicin in a Breast Cancer Model.
Wang T; Gantier MP; Xiang D; Bean AG; Bruce M; Zhou SF; Khasraw M; Ward A; Wang L; Wei MQ; AlShamaileh H; Chen L; She X; Lin J; Kong L; Shigdar S; Duan W
Theranostics; 2015; 5(12):1456-72. PubMed ID: 26681989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
